|Articles|May 15, 2012

Carotech Announces Tocotrienol Study on Cholesterol

The randomized, double-blind, placebo-controlled clinical trial is a collaboration between Ohio State University and the Government of Malaysia.

Researchers are conducting a yearlong trial on tocotrienol supplementation in subjects who have suffered ischemic stroke, according to tocotrienol supplier Carotech Inc. (Edison, NJ).

Carotech reports that the “Natural Tocotrienol Against Ischemic Stroke Event” trial will follow 210 volunteers taking palm tocotrienols for up to 12 months. Researchers will look for changes in platelet function and cholesterol as a result of tocotrienol supplementation.

The randomized, double-blind, placebo-controlled clinical trial is a collaboration between Ohio State University and the Government of Malaysia.

Visit Carotech online to stay updated on science involving tocotrienols.


Related to this article

SupplySide Global Vitaquest
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Laurentia Bliss
Live from SupplySide Global 2026, Laurentia Bliss talks about new athlete-focused research on Magtein, ThreoTech’s brain-targeted magnesium ingredient, and upcoming innovations like effervescent tablets and gummies.
Klaus Neumann
Live from SupplySide Global 2026, Klaus Neumann talks about Concordix's chewable supplement line spanning beauty and gut-immune health, including BeautyBioti, a Skin & Hair Vitality Complex, and FortiBiotic.